https://socictopen.socict.org/files/original/de0b45207513f733bda4212b6835d77a.pdf 3f6afcec83d88c3b63a4f6d3e4a6efe2 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Ivermectin - molecular mechanisms of antivirus and antiparasitic effects Creator An entity primarily responsible for making the resource Nosalska, T.N., Martynov, A.V., Bomuko, T.V. Description An account of the resource Specific highly affinity recognition of imports is crucial for the viral proteins nuclear localization. One of the drugs that affects the viral nuclear localization signal is ivermectin. It is shown that the addition of 5 mcM ivermectin to Vero-hSLAM cells 2 hours after SARS-COV-2 infection led to a decrease in the viral RNA load by 99.98% after 48 hours. Ivermectin for treatment SARS-COV-2 people have already approved in a number of states and countries, including Peru and the Northeastern region of Beni in Bolivia. It is important to note that about 70 tests around the world are currently checking the clinical efficacy of ivermectin for the treatment or prevention of SARS-COV-2; They include variations in dosing modes, combined therapy and prophylactic protocols. Scientists suggested that this drug can reduce viral load in infected patients with potential influence on the progression and dissemination of the disease. Possible directions for the further study of the recruitment of Ivermectin for the treatment of SARS-COV-2 may be in the development of an inhalation preparation for the effective delivery of high local concentration into the lungs with minimal systemic exposure and estimating the synergistic effects of ivermectin with other connections that also inhibit SARS-COV-2 replication. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource SARS-CoV-2, Ivermectin, cells culture, nuclear signal localization inhibitor, pilot clinical trials Identifier An unambiguous reference to the resource within a given context 10.5281/zenodo.4657699 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine (General)